Guardant Health, Inc. (NASDAQ:GH) Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC grew its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 30.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 39,594 shares of the company's stock after purchasing an additional 9,268 shares during the quarter. ProShare Advisors LLC's holdings in Guardant Health were worth $1,210,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in GH. Vanguard Group Inc. raised its position in shares of Guardant Health by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after purchasing an additional 350,606 shares during the last quarter. Deep Track Capital LP increased its stake in Guardant Health by 7.0% during the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock valued at $196,118,000 after purchasing an additional 419,006 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Guardant Health by 19.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after buying an additional 238,037 shares during the last quarter. Nikko Asset Management Americas Inc. raised its holdings in shares of Guardant Health by 15.6% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after buying an additional 197,729 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Guardant Health during the fourth quarter worth $36,438,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Guardant Health

In related news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now owns 2,202,672 shares of the company's stock, valued at approximately $107,952,954.72. This trade represents a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 107,132 shares of company stock valued at $5,248,393 over the last quarter. 6.10% of the stock is currently owned by insiders.

Guardant Health Price Performance

GH stock traded up $0.68 during mid-day trading on Tuesday, reaching $38.68. 950,857 shares of the company's stock were exchanged, compared to its average volume of 2,140,509. The company has a market cap of $4.79 billion, a price-to-earnings ratio of -10.84 and a beta of 1.49. The stock's 50 day moving average is $43.22 and its 200 day moving average is $40.31. Guardant Health, Inc. has a 12-month low of $20.14 and a 12-month high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $203.47 million during the quarter, compared to analysts' expectations of $189.91 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. The business's revenue was up 20.8% compared to the same quarter last year. On average, research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Mizuho assumed coverage on Guardant Health in a research report on Thursday, April 10th. They issued an "outperform" rating and a $55.00 target price on the stock. The Goldman Sachs Group increased their price objective on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. Guggenheim restated a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a research note on Monday, February 24th. JPMorgan Chase & Co. upped their target price on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Finally, Barclays increased their price target on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, May 1st. Twenty-one research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Guardant Health has a consensus rating of "Buy" and an average target price of $52.32.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.